Comparison of Proliferation Indices in Glioblastoma Multiforme by Whole Tissue Section vs Tissue Microarray

American Journal of Clinical Pathology

Volumn 120, Issue 6, 2003, Pages 902-908

  Chiesa Vottero, Andres G ^a   Rybicki, Lisa A ^a   Prayson, Richard A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cell proliferation; Glioblastoma multiforme; Ki 67; Proliferation indices; Tissue microarray

Indexed keywords

KI 67 ANTIGEN;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; DNA MICROARRAY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LABELING INDEX; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TISSUE SECTION;

EID: 0345258411     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/8UAUKFK3NBDMVTNU     Document Type: Article

References (36)

1. Rimm DL, Camp RL, Charette LA, et al. Tissue microarray: a new technology for amplification of tissue resources. Cancer J. 2001;7:24-31.
2. Bredel M, Piribauer M, Marosi C, et al. High expression of DNA topoisomerase 11α and Ki-67 antigen is associated with prolonged survival in glioblastoma patients. Eur J Cancer. 2002;38:1343-1347.
3. Kleihues P, Cavenee WK. Pathology and Genetics of Tumors of the Nervous System. Lyon, France: IARC Press; 2000. World Health Organization Classification of Tumors.
4. Burger PC, Green SB. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer. 1987;59:1617-1625.
5. Salmon I, Dewitte O, Pasteels JL, et al. Prognostic scoring in adult astrocytic tumors using patient age, histopathological grade, and DNA histogram type. J Neurosurg. 1994;80:877-883.
6. Sneed PK, Prados MD, McDermott MW, et al. Large effect of age on the survival of patients with glioblastoma treated with radiotherapy and brachytherapy boost. Neurosurgery. 1995;36:898-904.
7. Nazzaro JM, Neuwelt EA. The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J Neurosurg. 1990;73:331-344.
8. Leibel SA, Scott CB, Loeffler JS. Contemporary approaches to the treatment of malignant gliomas with radiation therapy. Semin Oncol. 1994;21:198-219.
9. Lesser GJ, Grossman S. The chemotherapy of high-grade astrocytomas. Semin Oncol. 1994;21:220-235.
10. Albert FK, Forsting M, Sartor K, et al. Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994;34:45-61.
11. Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms: a retrospective study of clinical parameters, therapy, and outcome. J Neurosurg. 1993;78:767-775.
12. Wood JR, Green SB, Shapiro WR. The prognostic importance of tumor size in malignant gliomas: a computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol. 1988;6:338-343.
13. Kreth FW, Warnke PC, Scheremet R, et al. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme. J Neurosurg. 1993;78:762-766.
14. Vaquero J, Zurita M, Morales C, et al. Prognostic significance of endothelial surface score and MIB-1 labeling index in glioblastoma. J Neurooncol. 2000;46:11-16.
15. Haapasalo HK, Sallinen PK, Helen PT, et al. Comparison of three quantitation methods for PCNA immunostaining: applicability and relation to survival in 83 astrocytic neoplasms. J Pathol. 1993;171:207-214.
16. Torp SH, Helseth E, Dalen A, et al. Relationships between Ki-67 labelling index, amplification of the epidermal growth factor receptor gene, and prognosis in human glioblastomas. Acta Neurochir (Wien). 1992;117:182-186.
17. Wakimoto H, Aoyagi M, Nakayama T, et al. Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas. Cancer. 1996;77:373-380.
18. Pigott TJ, Lowe JS, Palmer J. Statistical modelling in analysis of prognosis in glioblastoma multiforme: a study of clinical variables and Ki-67 index. Br J Neurosurg. 1991;5:61-66.
19. Schroeder R, Feisel KD, Ernestus RI. Ki-67 labelling is correlated with the time to recurrence in primary glioblastomas. J Neurooncol. 2002;56:127-132.
20. Prayson RA. Cell proliferation and tumors of the central nervous system, part II: radiolabeling, cytometric, and immunohistochemical techniques. J Neuropathol Exp Neurol. 2002;61:663-672.
21. Burger PC, Kleihues P. Cytologic composition of the untreated glioblastoma with implications for evaluation of needle biopsies. Cancer. 1989;63:2014-2023.
22. Deckert M, Reifenberger G, Wechsler W. Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67. J Cancer Res Clin Oncol. 1989;115:179-188.
23. Allegranza A, Girlando S, Arrigoni GL, et al. Proliferating cell nuclear antigen expression in central nervous system neoplasms. Virchows Arch A Pathol Anat Histopathol. 1991;419:417-423.
24. Coons SW, Johnson PC. Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index. J Neuropathol Exp Neurol. 1993;52:609-618.
25. Dalrymple SJ, Parisi JE, Roche PC, et al. Changes in proliferating cell nuclear antigen expression in glioblastoma multiforme cells along a stereotactic biopsy trajectory. Neurosurgery. 1994;35:1036-1045.
26. Carlsson J. A proliferation gradient in three dimensional colonies of cultured human glioma cells. Int J Cancer. 1977;20:129-136.
27. Haynes LW, Davis BE, Mitchell J, et al. Cell proliferation in explant cultures of malignant gliomas. Acta Neuropathol (Berl). 1978;42:87-90.
28. Maruno M, Kovach JS, Kelly P, et al. Transforming growth factor-α, epidermal growth factor receptor, and proliferating potential of benign and malignant gliomas. J Neurosurg. 1991;75:97-102.
29. Amin MR, Kurosaki M, Watanabe T, et al. A comparative study of MIB-1 staining indices of gliomas measured by NIH Image Analysis Program and conventional manual cell counting method. Neurol Res. 2000;22:495-500.
30. Giannini C, Scheithauer BW, Burger PC, et al. Cellular proliferation in pilocytic and diffuse astrocytomas. J Neuropathol Exp Neurol. 1999;58:40-53.
31. McKeever PE, Ross DA, Strawderman MS, et al. A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters. J Neuropathol Exp Neurol. 1997;56:798-805.
32. Grzybicki DM, Liu Y, Moore SA, et al. Interobserver variability associated with the MIB-1 labeling index: high levels suggest limited prognostic usefulness for patients with primary brain tumors. Cancer. 2001;92:2720-2726.
33. Prayson RA, Castilla EA, Hembury TA, et al. Interobserver variability in determining MIB-1 labeling indices in oligodendrogliomas. Ann Diagn Pathol. 2003;7:9-13.
34. Bubendorf L, Nocito A, Moch H, et al. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol. 2001;195:72-79.
35. Fernebro E, Dictor M, Bendahl PO, et al. Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med. 2002;126:702-705.
36. Nocito A, Bubendorf L, Maria Tinner E, et al. Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol. 2001;194:349-357.